Cost Is the Biggest Barrier to Entresto Adherence

As a prescriber, you know that Entresto (Sacubitril/Valsartan) is a cornerstone of guideline-directed medical therapy for heart failure. The evidence is clear: it reduces cardiovascular death by 20% and heart failure hospitalizations by 21% compared to Enalapril. But none of that matters if your patient can't afford to fill the prescription.

Cost-related non-adherence is one of the most common reasons patients stop taking Entresto or never start it in the first place. A 2023 study in the Journal of the American Heart Association found that out-of-pocket costs were the primary barrier to ARNI initiation in eligible heart failure patients. With brand-name Entresto still priced between $600 and $700 per month without insurance, this isn't surprising.

The good news: the financial landscape for Entresto has shifted significantly in 2026. Generic availability, Medicare price negotiation, and manufacturer savings programs have created real options for patients at every income level. This guide walks through what's available and how to integrate cost conversations into your prescribing workflow.

What Your Patients Are Actually Paying

Understanding the cost landscape helps you anticipate patient concerns and proactively address them:

Brand-Name Entresto

• Without insurance: $600–$700/month (60 tablets, 30-day supply at maintenance dose)
• With commercial insurance: Varies widely by plan — copays range from $30 to $200+/month depending on formulary tier and plan design
• Medicare Part D: Approximately $295/month maximum (negotiated price under the Inflation Reduction Act, effective January 2026)

Generic Sacubitril/Valsartan

• Cash price with discount card: $45–$255/month depending on pharmacy and coupon
• GoodRx best price: As low as $45/month
• Marley Drug: 60 tablets for approximately $70
• Insurance copay: Often preferred tier placement; typically $10–$50/month with commercial plans

The availability of generic Sacubitril/Valsartan since July 2025 has been a game-changer. For uninsured or underinsured patients, the difference between $700 and $45 per month is the difference between adherence and abandonment.

Manufacturer Savings Programs

Novartis Entresto Co-Pay Card

For patients on brand-name Entresto with commercial insurance:

• Eligible patients may pay as little as $10 per month
• Annual savings cap: $4,100
• Auto-renews each calendar year
• Enrollment: entresto.com/financial-support or enrollsupport.entresto.com
• Not valid for government-insured patients (Medicare, Medicaid, Tricare, VA)

This is one of the most generous manufacturer copay programs available. For commercially insured patients whose plan covers Entresto but with a high copay, this card can bring the cost down to a negligible amount. It's worth proactively mentioning to every eligible patient.

Novartis Patient Assistance Foundation (NPAF)

For uninsured or underinsured patients who meet income requirements:

• Provides Entresto at no cost to eligible patients
• Income-based eligibility criteria
• Application through the Novartis Patient Assistance Foundation

Important note: As generic versions have become widely available, Novartis has begun phasing out PAP support for brand-name Entresto, directing patients toward generic alternatives. For patients who need the brand for formulary or clinical reasons, it's worth checking current eligibility, but the generic pathway is now the primary cost-reduction strategy for most patients.

Coupon and Discount Card Options

For patients paying cash or facing high copays, discount cards can dramatically reduce costs — particularly for generic Sacubitril/Valsartan:

• GoodRx: Prices as low as $45/month for generic. Free to use; patients just show the coupon at the pharmacy.
• SingleCare: Competitive generic pricing; accepted at most major chains.
• RxSaver: Compares prices across nearby pharmacies with downloadable coupons.
• Optum Perks: Free discount card program with broad pharmacy acceptance.
• BuzzRx: Another free coupon option; particularly useful at independent pharmacies.

These programs work at the point of sale — patients don't need to enroll in advance for most of them. Consider keeping a list of these resources in your office or patient education materials. You can also direct patients to Medfinder for Providers for tools that help locate pharmacies with stock and competitive pricing.

Generic Alternatives and Therapeutic Substitution

Generic Sacubitril/Valsartan

Generic Sacubitril/Valsartan became available after Entresto's patent expired in July 2025. Multiple manufacturers now produce it in all three strengths (24/26 mg, 49/51 mg, and 97/103 mg). Key points for your prescribing decisions:

• Same active ingredients, same FDA-approved indications
• Bioequivalence established through standard FDA generic approval process
• Available at all major retail and mail-order pharmacies
• Cost savings of 80-90% compared to brand-name Entresto

For most patients, prescribing generic Sacubitril/Valsartan is the single most impactful thing you can do to improve affordability. Write "substitution permitted" or prescribe by generic name to ensure pharmacies can dispense the most cost-effective option.

Therapeutic Alternatives for Cost-Prohibitive Cases

For patients who truly cannot afford Entresto or its generic — even with discount programs — consider these guideline-recognized alternatives:

• Enalapril (ACE inhibitor): The comparator in the PARADIGM-HF trial. Less effective than Entresto but significantly cheaper (often under $10/month generic). A reasonable option when cost prevents ARNI access.
• Valsartan (ARB): For ACE-intolerant patients. Available as an inexpensive generic. One of Entresto's own components, though without the neprilysin inhibition benefit.
• Hydralazine/Isosorbide dinitrate (BiDil): An alternative vasodilator combination for patients who can't tolerate ACE inhibitors, ARBs, or ARNIs. Particularly beneficial in African American patients with HFrEF based on the A-HeFT trial.

The goal should always be to get patients on the most effective therapy they can sustain. An ACE inhibitor the patient actually takes is better than an ARNI they abandon after one fill.

Building Cost Conversations into Your Workflow

Cost discussions shouldn't be an afterthought — they should be part of the prescribing process. Here's how to integrate them efficiently:

At the Point of Prescribing

• Ask about insurance status before writing the prescription. This takes 30 seconds and determines which cost pathway is most relevant.
• Default to generic unless there's a specific clinical reason for brand-name. Write "Sacubitril/Valsartan" or ensure "substitution permitted" is indicated.
• Mention the copay card proactively for commercially insured patients on brand-name. Don't wait for the patient to come back complaining about cost.
• Use the teach-back method: "This medication costs about $X with your insurance. The manufacturer has a program that can bring that down to about $10. Would you like information on that?"

At Follow-Up Visits

• Ask directly: "Have you been able to fill your Entresto prescription each month?" Non-adherence due to cost often goes unreported unless you ask.
• Check for coverage changes: Insurance plans change annually. A medication that was affordable last year may not be this year.
• Reassess savings programs: Manufacturer programs have annual limits and eligibility changes. Verify the patient is still enrolled and benefiting.

Staff and Workflow Integration

• Train medical assistants and nurses to provide copay card information and savings resources during the visit — before the patient gets to the pharmacy.
• Create a one-page handout with savings options (copay card enrollment link, GoodRx instructions, patient assistance program contact information).
• Partner with your pharmacy team. Pharmacists are often the first to identify cost barriers when patients hesitate at the counter. Build a communication channel so they can flag issues back to your office.
• Leverage tools like Medfinder for Providers to help patients find pharmacies with Entresto in stock at competitive prices.

For Medicare Patients Specifically

The Inflation Reduction Act's Medicare price negotiation has capped Entresto at approximately $295/month for Medicare beneficiaries starting in 2026. Additionally:

• The $2,000 annual out-of-pocket cap for Medicare Part D (effective 2025) significantly reduces catastrophic spending on Entresto.
• Medicare's new $35/month insulin cap model may expand to other medications over time — stay informed on policy changes.
• Extra Help (Low-Income Subsidy) programs can further reduce costs for qualifying Medicare patients.

Final Thoughts

Entresto adherence is a clinical outcome. When patients stop taking their ARNI because of cost, they face increased hospitalization risk, disease progression, and mortality. The tools to address this are better than ever in 2026 — generic availability, manufacturer programs, discount cards, and Medicare negotiation have all made Entresto more accessible.

Your role as a provider is to connect patients with these resources proactively. A 60-second cost conversation at the point of prescribing can be the difference between a patient who fills their prescription and one who doesn't. Make it part of your workflow, not an afterthought.

For more clinical resources on Entresto, see our provider guides on managing Entresto shortages and helping patients find Entresto in stock.